Tyra Biosciences Inc (TYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -60,910 | -36,894 | -18,192 | -69,134 | -46,304 |
| Depreciation Amortization | 375 | 248 | 122 | 357 | 255 |
| Other Working Capital | -1,047 | -1,070 | -6,844 | 6,360 | 103 |
| Other Operating Activity | 11,398 | 5,430 | 2,886 | 12,278 | 9,339 |
| Operating Cash Flow | $-50,184 | $-32,286 | $-22,028 | $-50,139 | $-36,607 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -104,703 | -126,312 | 18,209 | -143,835 | N/A |
| PPE Investments | -658 | -606 | -136 | -770 | -167 |
| Investing Cash Flow | $-105,361 | $-126,918 | $18,073 | $-144,605 | $-167 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 201,851 | 201,108 | 200,484 | 1,537 | 1,213 |
| Common Stock Repurchased | -420 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 0 | -420 | -169 | 0 | 0 |
| Financing Cash Flow | $201,431 | $200,688 | $200,315 | $1,537 | $1,213 |
| Beginning Cash Position | 59,006 | 59,006 | 59,006 | 252,213 | 252,213 |
| End Cash Position | 104,892 | 100,490 | 255,366 | 59,006 | 216,652 |
| Net Cash Flow | $45,886 | $41,484 | $196,360 | $-193,207 | $-35,561 |
| Free Cash Flow | |||||
| Operating Cash Flow | -50,184 | -32,286 | -22,028 | -50,139 | -36,607 |
| Capital Expenditure | -658 | -606 | -136 | -770 | -167 |
| Free Cash Flow | -50,842 | -32,892 | -22,164 | -50,909 | -36,774 |